Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Jones

Showing results (11-20 of 264) with videos related to

Pageof 27
Sort By:
The Lancet. Haematology|September 3, 2018
Should an HLA-matched donor still be considered the perfect donor?Richard J Jones, Mary M Horowitz
Autoimmunity|October 30, 2008
Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantagesRobert A Brodsky, Richard J Jones
British Journal of Haematology|April 17, 2004
High-dose cyclophosphamide in severe aplastic anaemiaRichard J Jones, Robert A Brodsky
Lancet (London, England)|May 12, 2005
Aplastic anaemiaRobert A Brodsky, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 6, 2009
Cancer Stem Cells in Hematopoietic MalignanciesRichard J Jones, Scott A Armstrong
Blood|June 11, 2021
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neitherRichard J Jones, Michael R DeBaun
Blood Reviews|November 26, 2022
The development of post-transplant cyclophosphamide: Half a century of translational team sciencePaul V O'Donnell, Richard J Jones
Current Opinion in Oncology|March 7, 2002
Bone marrow transplantation for multiple myeloma: where we are todayCarol Ann Huff, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2008
Cancer stem cells in hematopoietic malignanciesRichard J Jones, Scott A Armstrong
Stem Cells (Dayton, Ohio)|November 3, 2011
Concise review: Cancer stem cells and minimal residual diseaseGabriel Ghiaur, Jonathan Gerber, Richard J Jones
Pageof 27

Showing results (11-20 of 264) with videos related to

Sort By:
Pageof 27
The Lancet. Haematology|September 3, 2018
Should an HLA-matched donor still be considered the perfect donor?Richard J Jones, Mary M Horowitz
Autoimmunity|October 30, 2008
Intensive immunosuppression with high dose cyclophosphamide but without stem cell rescue for severe autoimmunity: advantages and disadvantagesRobert A Brodsky, Richard J Jones
British Journal of Haematology|April 17, 2004
High-dose cyclophosphamide in severe aplastic anaemiaRichard J Jones, Robert A Brodsky
Lancet (London, England)|May 12, 2005
Aplastic anaemiaRobert A Brodsky, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 6, 2009
Cancer Stem Cells in Hematopoietic MalignanciesRichard J Jones, Scott A Armstrong
Blood|June 11, 2021
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neitherRichard J Jones, Michael R DeBaun
Blood Reviews|November 26, 2022
The development of post-transplant cyclophosphamide: Half a century of translational team sciencePaul V O'Donnell, Richard J Jones
Current Opinion in Oncology|March 7, 2002
Bone marrow transplantation for multiple myeloma: where we are todayCarol Ann Huff, Richard J Jones
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2008
Cancer stem cells in hematopoietic malignanciesRichard J Jones, Scott A Armstrong
Stem Cells (Dayton, Ohio)|November 3, 2011
Concise review: Cancer stem cells and minimal residual diseaseGabriel Ghiaur, Jonathan Gerber, Richard J Jones
Pageof 27